Latest Cellceutix Corp (CTIX) Headlines
Cellceutix Expands to Gram-Negative Bacterial Infections
Marketwire - Wed Mar 05, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to inform shareholders that several preclinical investigations are underway with several lead compounds in animal models of Gram-negative bacterial infections. The Company is focusing this research on some of the most difficult to treat multi-drug resistant or "pandrug-resistant" bacterium where there is a significant and growing medical need for new therapies.
Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
Marketwire - Wed Feb 26, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the first patients have been enrolled and treated in the Company's Phase 2b clinical trial of Brilacidin in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections
Marketwire - Mon Feb 24, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the Company has concluded negotiations with formulation developers and selected Dr. Reddy's Custom Pharmaceutical Services (CPS), part of the Pharmaceutical Services and Active Ingredients (PSAI) business unit of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's"), a New York Stock Exchange-listed company traded under the ticker "RDY", for the formulation of the Company's defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections.
Cellceutix Submits Investigational New Drug Application (IND) for Clinical Trial of New Anti-Psoriasis Drug, Enrollment Underway in Phase 2b Clinical Trials of Brilacidin
Marketwire - Tue Feb 18, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the Company has submitted an Investigational New Drug Application ("IND") to the U.S. Food and Drug Administration ("FDA") for the clinical development of Prurisol as a potential new treatment for psoriasis.
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 05, 2:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbm7xt/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2013" report to their offering. 'Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. Scope - A snapshot of the global therapeutic scenario for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some Key Topics Covered: Introduction Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Overview Therapeutics Development Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Overview Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Comparative Analysis brilacidin - Drug Profile LTX-109 - Drug Profile PGC Anti-MRSA - Drug Profile IMV-0123 - Drug Profile SM-295291 - Drug Profile SM-369926 - Drug Profile ASN-100 - Drug Profile Antibiotic Program - Drug Profile Drugs for Bacterial Infections - Drug Profile Human Cathelicidin LL-37 Derivatives - Drug Profile Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Recent Pipeline Updates Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Dormant Projects Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Discontinued Products Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Product Development Milestones Companies Mentioned Dainippon Sumitomo Pharma Co., Ltd. Immtech Pharmaceuticals, Inc. Cellceutix Corporation Lytix Biopharma AS PharmaIN Corporation ImmuVen, Inc. Arsanis Biosciences GmbH For more information visit http://www.researchandmarkets.com/research/kb...llinsuscep About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cellceutix Files With FDA for Phase 2b Clinical Trial of Novel Antibiotic Brilacidin; Enrollment of Patients Expected to Start Mid-February
Marketwire - Mon Feb 03, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the protocol for the Phase 2b trial of Brilacidin, Cellceutix's lead compound in a novel class of synthetic immunomodulatory antimicrobials known as defensin-mimetics, was sent to the U.S. Food and Drug Administration.
Enterococcus Faecium Infections - Pipeline Review, H2 2013 Research Report
M2 - Wed Jan 29, 2:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdqfb5/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2013" report to their offering. 'Enterococcus Faecium Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Dainippon Sumitomo Pharma Co., Ltd. Aquapharm Biodiscovery Limited Cellceutix Corporation Omnia Molecular Ltd. Biota Pharmaceuticals, Inc. Abgentis Limited Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/zd...terococcus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Plague - Latest Pipeline Review Report
M2 - Mon Jan 27, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/9r77ph/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H2 2013" report to their offering. 'Plague - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Plague, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plague. Scope - A snapshot of the global therapeutic scenario for Plague. - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Plague pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Plague - Companies Involved in Therapeutics Development - Takeda Pharmaceutical Company Limited - Summit Corporation plc - Mucosis B.V. - iBio, Inc. - Cellceutix Corporation Drug Profiles - rF1V Vaccine - Flagellin/F1/V Vaccine - PMX-30016 - SMT-15000 - Subunit Vaccine For Plague - Plague Vaccine - Yersinia Pestis Vaccine - Subunit Vaccine For Anthrax-Plague Combination - Yersinia Pestis Vaccine - Yersinia Pestis Vaccine - tPA-V DNA Vaccine - Small Molecule to Inhibit YoPH for Plague For more information visit http://www.researchandmarkets.com/research/9r...e_pipeline
Bacteremia - Pipeline Review, H2 2013 Report
M2 - Mon Jan 27, 2:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/qv84kq/bacteremia) has announced the addition of the "Bacteremia - Pipeline Review, H2 2013" report to their offering. 'Bacteremia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacteremia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacteremia. Scope - A snapshot of the global therapeutic scenario for Bacteremia. - A review of the Bacteremia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacteremia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bacteremia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bacteremia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Cubist Pharmaceuticals, Inc. Nabriva Therapeutics AG Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/qv84kq/bacteremia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bacterial Conjunctivitis - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Bacterial Conjunctivitis
M2 - Wed Jan 22, 5:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/s6nmg2/bacterial) has announced the addition of the "Bacterial Conjunctivitis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Bacterial Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis. Bacterial Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacterial Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Cellceutix Corporation -China Grand Wuhan General Pharmaceutical Research Institute -Daiichi Sankyo Company, Limited -EyeGate Pharmaceuticals, Inc. -InSite Vision Incorporated -NovaBay Pharmaceuticals, Inc. -Ocular Therapeutix, Inc. For more information visit http://www.researchandmarkets.com/research/s6nmg2/bacterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cellceutix Sees Increased Valuation Potential for Its Novel Antibiotic Brilacidin
Marketwire - Tue Jan 21, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to inform shareholders of an extremely productive Biotech Showcase 2014 conference, notably the Company's increased optimism regarding the potential value of Brilacidin, the first drug candidate from the Company's franchise antibiotic platform that has the potential to treat many indications of great unmet medical need.
Cellceutix Provides Updates on Clinical Trials and Developments of Its Anti-Cancer, Anti-Psoriasis, and Antibiotic Compounds
Marketwire - Wed Jan 15, 7:02AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, today provides shareholders with an update on the current status of the Company's compounds in development.
Cellceutix Corporation to Present at Biotech Showcase 2014
Marketwire - Mon Jan 13, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, today announced that the Company will be presenting a corporate overview at the Biotech Showcase(TM) 2014 on Wednesday, January 15th, at 10:30 a.m. PST. The conference is being held in San Francisco at the Parc 55 Wyndham Union Square Hotel.
Video Insight to Donate $250,000 in Video Surveillance Systems To U.S. Schools, Colleges Via Security Grant
PR Newswire - Tue Jan 07, 1:45PM CST
In an effort to help campuses prevent and combat violence, Video Insight - a leading developer of enterprise IP video surveillance software - will donate over $250,000 in video surveillance software and hardware to schools and colleges nationwide in 2014 via a new Video Insight School Security Grant.
Cellceutix Submits Application to Institutional Review Board to Commence Clinical Trials of Anti-Psoriasis Drug Prurisol
Marketwire - Mon Jan 06, 7:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that it has today submitted the application to the Institutional Review Board ("IRB") responsible for the planned clinical study of the Company's psoriasis drug Prurisol.
Cellceutix Corporation files application with the US FDA for orphan drug designation for Brilacidin for Oral Mucositis
M2 - Mon Dec 23, 7:15AM CST
Biopharmaceutical company Cellceutix Corporation (OTCQB:CTIX) reported on Friday the submission of an application with the US Food and Drug Administration for its novel antibiotic Brilacidin-OM.
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis With US FDA
Marketwire - Fri Dec 20, 6:59AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that it has filed an application with the U.S. Food and Drug Administration requesting Orphan Drug designation for its novel antibiotic Brilacidin(TM)-OM as a drug candidate for the prevention of radiation or chemotherapy-induced oral mucositis in head and neck cancer.
Tycoon Wants to Evict Kinango Residents - Rep
by Alloys Musyoka - All Africa Global Media - Wed Dec 18, 6:35AM CST
More than 3,000 residents face eviction at Nyango in Kinango. Puma ward representative James Dawa said the residents will have nowhere to call home if they are evicted from the land that they have lived on for more than 60 years.
Cellceutix Corporation to begin planned Phase 2b clinical trial of novel antibiotic Brilacidin for ABSSSI upon IRB's review
M2 - Tue Dec 17, 5:56AM CST
Biopharmaceutical company Cellceutix Corporation (OTCQB:CTIX) reported on Monday the submission of an application to the Institutional Review Board (IRB) for its planned Phase 2b clinical trial of its novel antibiotic Brilacidin as a drug candidate for Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Cellceutix Submits Application for IRB Review to Commence Phase 2b Clinical Trial of Novel Antibiotic Brilacidin
Marketwire - Mon Dec 16, 6:18AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that it has submitted the application to the Institutional Review Board ("IRB") responsible for the Company's planned Phase 2b clinical trial of its novel antibiotic Brilacidin as a drug candidate for Acute Bacterial Skin and Skin Structure Infections ("ABSSSI").
Cellceutix Expands to Gram-Negative Bacterial Infections
Marketwire - Wed Mar 05, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to inform shareholders that several preclinical investigations are underway with several lead compounds in animal models of Gram-negative bacterial infections. The Company is focusing this research on some of the most difficult to treat multi-drug resistant or "pandrug-resistant" bacterium where there is a significant and growing medical need for new therapies.
Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
Marketwire - Wed Feb 26, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the first patients have been enrolled and treated in the Company's Phase 2b clinical trial of Brilacidin in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections
Marketwire - Mon Feb 24, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the Company has concluded negotiations with formulation developers and selected Dr. Reddy's Custom Pharmaceutical Services (CPS), part of the Pharmaceutical Services and Active Ingredients (PSAI) business unit of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's"), a New York Stock Exchange-listed company traded under the ticker "RDY", for the formulation of the Company's defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections.
Cellceutix Submits Investigational New Drug Application (IND) for Clinical Trial of New Anti-Psoriasis Drug, Enrollment Underway in Phase 2b Clinical Trials of Brilacidin
Marketwire - Tue Feb 18, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the Company has submitted an Investigational New Drug Application ("IND") to the U.S. Food and Drug Administration ("FDA") for the clinical development of Prurisol as a potential new treatment for psoriasis.
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 05, 2:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbm7xt/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2013" report to their offering. 'Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. Scope - A snapshot of the global therapeutic scenario for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some Key Topics Covered: Introduction Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Overview Therapeutics Development Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Overview Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Comparative Analysis brilacidin - Drug Profile LTX-109 - Drug Profile PGC Anti-MRSA - Drug Profile IMV-0123 - Drug Profile SM-295291 - Drug Profile SM-369926 - Drug Profile ASN-100 - Drug Profile Antibiotic Program - Drug Profile Drugs for Bacterial Infections - Drug Profile Human Cathelicidin LL-37 Derivatives - Drug Profile Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Recent Pipeline Updates Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Dormant Projects Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Discontinued Products Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Product Development Milestones Companies Mentioned Dainippon Sumitomo Pharma Co., Ltd. Immtech Pharmaceuticals, Inc. Cellceutix Corporation Lytix Biopharma AS PharmaIN Corporation ImmuVen, Inc. Arsanis Biosciences GmbH For more information visit http://www.researchandmarkets.com/research/kb...llinsuscep About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cellceutix Files With FDA for Phase 2b Clinical Trial of Novel Antibiotic Brilacidin; Enrollment of Patients Expected to Start Mid-February
Marketwire - Mon Feb 03, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the protocol for the Phase 2b trial of Brilacidin, Cellceutix's lead compound in a novel class of synthetic immunomodulatory antimicrobials known as defensin-mimetics, was sent to the U.S. Food and Drug Administration.
Enterococcus Faecium Infections - Pipeline Review, H2 2013 Research Report
M2 - Wed Jan 29, 2:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdqfb5/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2013" report to their offering. 'Enterococcus Faecium Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Dainippon Sumitomo Pharma Co., Ltd. Aquapharm Biodiscovery Limited Cellceutix Corporation Omnia Molecular Ltd. Biota Pharmaceuticals, Inc. Abgentis Limited Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/zd...terococcus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Plague - Latest Pipeline Review Report
M2 - Mon Jan 27, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/9r77ph/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H2 2013" report to their offering. 'Plague - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Plague, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plague. Scope - A snapshot of the global therapeutic scenario for Plague. - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Plague pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Plague - Companies Involved in Therapeutics Development - Takeda Pharmaceutical Company Limited - Summit Corporation plc - Mucosis B.V. - iBio, Inc. - Cellceutix Corporation Drug Profiles - rF1V Vaccine - Flagellin/F1/V Vaccine - PMX-30016 - SMT-15000 - Subunit Vaccine For Plague - Plague Vaccine - Yersinia Pestis Vaccine - Subunit Vaccine For Anthrax-Plague Combination - Yersinia Pestis Vaccine - Yersinia Pestis Vaccine - tPA-V DNA Vaccine - Small Molecule to Inhibit YoPH for Plague For more information visit http://www.researchandmarkets.com/research/9r...e_pipeline
Bacteremia - Pipeline Review, H2 2013 Report
M2 - Mon Jan 27, 2:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/qv84kq/bacteremia) has announced the addition of the "Bacteremia - Pipeline Review, H2 2013" report to their offering. 'Bacteremia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacteremia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacteremia. Scope - A snapshot of the global therapeutic scenario for Bacteremia. - A review of the Bacteremia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacteremia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bacteremia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bacteremia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Cubist Pharmaceuticals, Inc. Nabriva Therapeutics AG Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/qv84kq/bacteremia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bacterial Conjunctivitis - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Bacterial Conjunctivitis
M2 - Wed Jan 22, 5:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/s6nmg2/bacterial) has announced the addition of the "Bacterial Conjunctivitis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Bacterial Conjunctivitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis. Bacterial Conjunctivitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacterial Conjunctivitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Cellceutix Corporation -China Grand Wuhan General Pharmaceutical Research Institute -Daiichi Sankyo Company, Limited -EyeGate Pharmaceuticals, Inc. -InSite Vision Incorporated -NovaBay Pharmaceuticals, Inc. -Ocular Therapeutix, Inc. For more information visit http://www.researchandmarkets.com/research/s6nmg2/bacterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cellceutix Sees Increased Valuation Potential for Its Novel Antibiotic Brilacidin
Marketwire - Tue Jan 21, 6:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to inform shareholders of an extremely productive Biotech Showcase 2014 conference, notably the Company's increased optimism regarding the potential value of Brilacidin, the first drug candidate from the Company's franchise antibiotic platform that has the potential to treat many indications of great unmet medical need.
Cellceutix Provides Updates on Clinical Trials and Developments of Its Anti-Cancer, Anti-Psoriasis, and Antibiotic Compounds
Marketwire - Wed Jan 15, 7:02AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, today provides shareholders with an update on the current status of the Company's compounds in development.
Cellceutix Corporation to Present at Biotech Showcase 2014
Marketwire - Mon Jan 13, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, today announced that the Company will be presenting a corporate overview at the Biotech Showcase(TM) 2014 on Wednesday, January 15th, at 10:30 a.m. PST. The conference is being held in San Francisco at the Parc 55 Wyndham Union Square Hotel.
Video Insight to Donate $250,000 in Video Surveillance Systems To U.S. Schools, Colleges Via Security Grant
PR Newswire - Tue Jan 07, 1:45PM CST
In an effort to help campuses prevent and combat violence, Video Insight - a leading developer of enterprise IP video surveillance software - will donate over $250,000 in video surveillance software and hardware to schools and colleges nationwide in 2014 via a new Video Insight School Security Grant.
Cellceutix Submits Application to Institutional Review Board to Commence Clinical Trials of Anti-Psoriasis Drug Prurisol
Marketwire - Mon Jan 06, 7:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that it has today submitted the application to the Institutional Review Board ("IRB") responsible for the planned clinical study of the Company's psoriasis drug Prurisol.
Cellceutix Corporation files application with the US FDA for orphan drug designation for Brilacidin for Oral Mucositis
M2 - Mon Dec 23, 7:15AM CST
Biopharmaceutical company Cellceutix Corporation (OTCQB:CTIX) reported on Friday the submission of an application with the US Food and Drug Administration for its novel antibiotic Brilacidin-OM.
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis With US FDA
Marketwire - Fri Dec 20, 6:59AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that it has filed an application with the U.S. Food and Drug Administration requesting Orphan Drug designation for its novel antibiotic Brilacidin(TM)-OM as a drug candidate for the prevention of radiation or chemotherapy-induced oral mucositis in head and neck cancer.
Tycoon Wants to Evict Kinango Residents - Rep
by Alloys Musyoka - All Africa Global Media - Wed Dec 18, 6:35AM CST
More than 3,000 residents face eviction at Nyango in Kinango. Puma ward representative James Dawa said the residents will have nowhere to call home if they are evicted from the land that they have lived on for more than 60 years.
Cellceutix Corporation to begin planned Phase 2b clinical trial of novel antibiotic Brilacidin for ABSSSI upon IRB's review
M2 - Tue Dec 17, 5:56AM CST
Biopharmaceutical company Cellceutix Corporation (OTCQB:CTIX) reported on Monday the submission of an application to the Institutional Review Board (IRB) for its planned Phase 2b clinical trial of its novel antibiotic Brilacidin as a drug candidate for Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Cellceutix Submits Application for IRB Review to Commence Phase 2b Clinical Trial of Novel Antibiotic Brilacidin
Marketwire - Mon Dec 16, 6:18AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that it has submitted the application to the Institutional Review Board ("IRB") responsible for the Company's planned Phase 2b clinical trial of its novel antibiotic Brilacidin as a drug candidate for Acute Bacterial Skin and Skin Structure Infections ("ABSSSI").
